Induction of p53 suppresses chronic myeloid leukemia

References

• Rowley JD. Chromosome translocations: dangerous liaisons revisited. Nat Rev Cancer. 2001;1:245–250.
   PubMed Web of Science ®Google Scholar
• Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005;5:172–183.
   PubMed Web of Science ®Google Scholar
• An X, Tiwari AK, Sun Y, et al. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. Leuk Res. 2010;34:1255–1268.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Talpaz M, Giles F, et al. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med. 2006;145:913–923.
   PubMed Web of Science ®Google Scholar
• Corbin AS, Agarwal A, Loriaux M, et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Investig. 2011;121:396–409.
   PubMed Web of Science ®Google Scholar
• Valent P, Hadzijusufovic E, Schernthaner G-H, et al. Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood. 2014;125:901–906.
   PubMed Web of Science ®Google Scholar
• Cortes J, Hochhaus A, Kim DW, et al. Four-year (Yr) follow-up of patients (Pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) receiving dasatinib or imatinib: efficacy based on early response. Blood. 2013;122:653.
   Web of Science ®Google Scholar
• Saglio G, Hochhaus A, Hughes TP, et al. ENESTnd update: nilotinib vs imatinib in patients with newly diagnosed CML-CP and the impact of early molecular response and Sokal risk at diagnosis on long-term outcomes. Blood. 2013;122:92.
   Web of Science ®Google Scholar
• Cortes JE, Kim DW, Pinilla-Ibarz J, et al. Ponatinib in patients with CML and Ph + ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I BCR‐ABL mutation: 2-year follow‐up of the PACE trial. Blood. 2013;122:650.
   Web of Science ®Google Scholar
• Kantarjian HM, Fojo T, Mathisen M, et al. Cancer drugs in the United States: JustumPretium—the just price. J Clin Oncol. 2013;31:3600–3604.
   PubMed Web of Science ®Google Scholar
• Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol. 2007;8:275–283.
   PubMed Web of Science ®Google Scholar
• Liu Y, Elf SE, Miyata Y, et al. p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell. 2009;4:37–48.
   PubMed Web of Science ®Google Scholar
• Haupt Y, Maya R, Kazaz A, et al. Mdm2 promotes the rapid degradation of p53. Nature. 1997;387:296–299.
   PubMed Web of Science ®Google Scholar
• Momand J, Zambetti GP, Olson DC, et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992;69:1237–1245.
   PubMed Web of Science ®Google Scholar
• Wu X, Bayle JH, Olson D, et al. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 1993;7:1126–1132.
   PubMed Web of Science ®Google Scholar
• Feki A, Irminger-Finger I. Mutational spectrum of p53 mutations in primary breast and ovarian tumors. Crit Rev Oncol Hematol. 2004;52:103–116.
   PubMed Web of Science ®Google Scholar
• Oliner JD, Kinzler KW, Meltzer PS, et al. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 1992;358:80–83.
   PubMed Web of Science ®Google Scholar
• Momand J, Jung D, Wilczynski S, et al. The MDM2 gene amplification database. Nucleic Acids Res. 1998;26:3453–3459.
   PubMed Web of Science ®Google Scholar
• Bueso-Ramos CE, Yang Y, deLeon E, et al. The human MDM-2 oncogene is overexpressed in leukemias. Blood. 1993;82:2617–2623.
   PubMed Web of Science ®Google Scholar
• Merritt AJ, Potten CS, Kemp CJ, et al. The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res. 1994;54:614–617.
   PubMed Web of Science ®Google Scholar
• Lowe SW, Schmitt EM, Smith SW, et al. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature. 1993;362:847–849.
   PubMed Web of Science ®Google Scholar
• Mendrysa SM, O'Leary KA, McElwee MK, et al. Tumor suppression and normal aging in mice with constitutively high p53 activity. Genes Dev. 2006;20:16–21.
   PubMed Web of Science ®Google Scholar
• Tovar C, Rosinski J, Filipovic Z, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA. 2006;103:1888–1893.
   PubMed Web of Science ®Google Scholar
• Shangary S, Qin D, McEachern D, et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA. 2008;105:3933–3938.
   PubMed Web of Science ®Google Scholar
• Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303:844–848.
   PubMed Web of Science ®Google Scholar
• Peterson LF, Mitrikeska E, Giannola D, et al. p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells. Leukemia. 2011;25:761–769.
   PubMed Web of Science ®Google Scholar
• Konig H, Holyoake TL, Bhatia R. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood. 2008;111:2329–2338.
   PubMed Web of Science ®Google Scholar
• Konig H, Holtz M, Modi H, et al. Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors. Leukemia. 2008;22:748–755.
   PubMed Web of Science ®Google Scholar
• Godar S, Ince TA, Bell GW, et al. Growth-inhibitory and tumor-suppressive functions of p53 depend on its repression of CD44 expression. Cell. 2008;134:62–73.
   PubMed Web of Science ®Google Scholar
• Krause DS, Lazarides K, von Andrian UH, et al. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med. 2006;12:1175–1180.
   PubMed Web of Science ®Google Scholar
• Souza LR, Silva E, Calloway E, et al. Genistein protects hematopoietic stem cells against G-CSF–induced DNA damage. Cancer Prev Res. 2014;7:534–544.
   PubMed Web of Science ®Google Scholar
• Forsberg EC, Passegué E, Prohaska SS, et al. Molecular signatures of quiescent, mobilized and leukemia-initiating hematopoietic stem cells. PLoS One. 2010;5:e8785.
   PubMed Web of Science ®Google Scholar
• Secchiero P, Barbarotto E, Tiribelli M, et al. Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2006;107:4122–4129.
   PubMed Web of Science ®Google Scholar
• Petzer AL, Hogge DE, Landsdorp PM, et al. Self-renewal of primitive human hematopoietic cells (long-term-culture-initiating cells) in vitro and their expansion in defined medium. Proc Natl Acad Sci USA. 1996;93:1470–1474.
   PubMed Web of Science ®Google Scholar
• Petzer AL, Eaves CJ, Lansdorp PM, et al. Characterization of primitive subpopulations of normal and leukemic cells present in the blood of patients with newly diagnosed as well as established chronic myeloid leukemia. Blood. 1996;88:2162–2171.
   PubMed Web of Science ®Google Scholar
• Copland M, Pellicano F, Richmond L, et al. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood. 2008;111:2843–2853.
   PubMed Web of Science ®Google Scholar
• Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99:319–325.
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545–15550.
   PubMed Web of Science ®Google Scholar
• Mootha VK, Lindgren CM, Eriksson K-F, et al. PGC-1[alpha]-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34:267–273.
   PubMed Web of Science ®Google Scholar
• Nikulenkov F, Spinnler C, Li H, et al. Insights into p53 transcriptional function via genome-wide chromatin occupancy and gene expression analysis. Cell Death Differ. 2012;19:1992–2002.
   PubMed Web of Science ®Google Scholar
• Zhang B, Strauss AC, Chu S, et al. Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell. 2010;17:427–442.
   PubMed Web of Science ®Google Scholar
• Gallipoli P, Cook A, Rhodes S, et al. JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo. Blood. 2014;124:1492–1501.
   PubMed Web of Science ®Google Scholar
• Bhatia R, Holtz M, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood. 2003;101:4701–4707.
   PubMed Web of Science ®Google Scholar
• Rousselot P, Charbonnier A, Cony-Makhoul P, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014;32:424–430.
   PubMed Web of Science ®Google Scholar
• Chomel JC, Bonnet ML, Sorel N, et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood. 2011;118:3657–3660.
   PubMed Web of Science ®Google Scholar
• Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122:515–522.
   PubMed Web of Science ®Google Scholar
• Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28:2381–2388.
   PubMed Web of Science ®Google Scholar
• Deininger M, O'Brien SG, Guilhot F, et al. International randomized study of interferon Vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract]. Blood. 2009;114:1126.
   Web of Science ®Google Scholar
• Mitani N, Niwa Y, Okamoto Y. Surveyor nuclease-based detection of p53 gene mutations in haematological malignancy. Ann Clin Biochem. 2007;44:557–559.
   PubMed Web of Science ®Google Scholar
• Kojima K, Konopleva M, Samudio IJ, et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood. 2005;106:3150–3159.
   PubMed Web of Science ®Google Scholar
• Stuhmer T, Chatterjee M, Hildebrandt M, et al. Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood. 2005;106:3609–3617.
   PubMed Web of Science ®Google Scholar
• Kazemi A, Safa M, Shahbazi A. RITA enhances chemosensitivity of pre-B ALL cells to doxorubicin by inducing p53-dependent apoptosis. Hematology. 2011;16:225–231.
   PubMed Web of Science ®Google Scholar
• Gu L, Zhu N, Findley HW, et al. MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2. Leukemia. 2008;22:730–739.
   PubMed Web of Science ®Google Scholar
• Andreeff M, Kelly KR, Yee K, et al. Results of the phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia. Clin Cancer Res. 2016;22:868–876.
   PubMed Web of Science ®Google Scholar
• Hurtz C, Hatzi K, Cerchietti L, et al. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J Exp Med. 2011;208:2163–2174.
   PubMed Web of Science ®Google Scholar
• Li L, Wang L, Wang Z, et al. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell. 2012;21:266–281.
   PubMed Web of Science ®Google Scholar
• Chuikov S, Levi BP, Smith ML, et al. Prdm16 promotes stem cell maintenance in multiple tissues, partly by regulating oxidative stress. Nat Cell Biol. 2010;12:999–1006.
   PubMed Web of Science ®Google Scholar
• Shen X, Kim W, Fujiwara Y, et al. Jumonji modulates polycomb activity and self-renewal versus differentiation of stem cells. Cell. 2009;139:1303–1314.
   PubMed Web of Science ®Google Scholar
• Essers MAG, Offner S, Blanco-Bose WE, et al. IFN[agr] activates dormant haematopoietic stem cells in vivo. Nature. 2009;458:904–908.
   PubMed Web of Science ®Google Scholar
• Kojima K, McQueen T, Chen Y, et al. p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α-mediated down-regulation of CXCL12. Blood. 2011;118:4431–4439.
   PubMed Web of Science ®Google Scholar
• Abraham SA, Hopcroft LEM, Carrick E, et al. Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells. Nature. 2016;534:341–346.
   PubMed Web of Science ®Google Scholar